Analyst Price Targets — AMGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 10:49 am | David Amsellem | Piper Sandler | $457.00 | $442.36 | TheFly | Amgen price target raised to $457 from $427 at Piper Sandler |
| August 19, 2026 1:04 pm | — | Morgan Stanley | $362.00 | $440.28 | TheFly | Amgen price target raised to $362 from $351 at Morgan Stanley |
| August 19, 2026 12:40 pm | — | Argus Research | $460.00 | $439.95 | TheFly | Amgen price target raised to $460 from $375 at Argus |
| August 18, 2026 11:20 am | — | Cantor Fitzgerald | $400.00 | $419.38 | TheFly | Amgen price target raised to $400 from $350 at Cantor Fitzgerald |
| August 18, 2026 11:03 am | — | Mizuho Securities | $352.00 | $419.38 | TheFly | Amgen price target raised to $352 from $303 at Mizuho |
| August 14, 2026 9:13 am | Emily Field | Barclays | $380.00 | $417.84 | TheFly | Amgen price target raised to $380 from $360 at Barclays |
| August 10, 2026 11:28 am | Vamil Divan | Guggenheim | $388.00 | $410.95 | StreetInsider | Amgen (AMGN) PT Raised to $388 at Guggenheim |
| August 6, 2026 11:51 am | — | Bernstein | $345.00 | $407.83 | TheFly | Amgen price target raised to $345 from $335 at Bernstein |
| August 5, 2026 3:02 pm | Louise Chen | Scotiabank | $450.00 | $406.25 | TheFly | Amgen price target raised to $450 from $385 at Scotiabank |
| August 5, 2026 11:46 am | — | Oppenheimer | $450.00 | $390.02 | TheFly | Amgen price target raised to $450 from $400 at Oppenheimer |
Latest News for AMGN
Athena Investment Management decreased its holdings in Amgen Inc. (NASDAQ: AMGN) by 42.4% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,236 shares of the medical research company's stock after selling 1,647 shares during the quarter. Athena Investment Management's holdings in Amgen
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.
Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many High-Risk Patients Undertreated and Not Achieving Recommended LDL-C Goals THOUSAND OAKS, Calif., Aug. 31, 2026 /PRNewswire/ -- Amgen (NASDAQ:…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.